Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer

The interaction of programmed cell death-1 and its ligand is widely studied in cancer. Monoclonal antibodies blocking these molecules have had great success but little is known about them in thyroid cancer. We investigated the role of PD-L1 in thyroid cancer with respect to BRAF mutation and MAP kin...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Brauner, Eran, Gunda, Viswanath, Borre, Pierre Vanden, Zurakowski, David, Kim, Yon Seon, Dennett, Kate Virginia, Amin, Salma, Freeman, Gordon James, Parangi, Sareh
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4941380/
https://ncbi.nlm.nih.gov/pubmed/26943572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7839
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi